Increased plasma thioredoxin levels in patients with sepsis: Positive association with macrophage migration inhibitory factor

Intensive Care Medicine

Volumn 36, Issue 2, 2010, Pages 336-341

  Leaver, Susannah K ^a   MacCallum, Niall S ^a   Pingle, Vasisht ^b   Hacking, Matthew B ^c   Quinlan, Gregory J ^a   Evans, Timothy W ^a,b   Burke Gaffney, Anne ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Cytokines; Macrophage inflammatory factor; Procalcitonin; Sepsis; Systemic inflammatory response syndrome; Thioredoxin

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; PROCALCITONIN; THIOREDOXIN; CALCITONIN; PROTEIN PRECURSOR;

AGED; APACHE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS RESECTION; FEMALE; HUMAN; MALE; NEUTROPENIA; PROTEIN BLOOD LEVEL; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; BLOOD; REVIEW;

CALCITONIN; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; NEUTROPENIA; PROTEIN PRECURSORS; SEPSIS; THIOREDOXINS;

EID: 77951239929     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-009-1640-z     Document Type: Article

References (29)

1. Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE Jr, Russell JA, Mayers I, Rosenfeld BA, Morris PE, Yan SB, Helterbrand JD (2001) Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 29:2051-2059
2. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP (2000) Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6:164-170
3. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, David JR (1999) Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 189:341-346
4. Calandra T (2003) Macrophage migration inhibitory factor and host innate immune responses to microbes. Scand J Infect Dis 35:573-576
5. Calandra T, Froidevaux C, Martin C, Roger T (2003) Macrophage migration inhibitory factor and host innate immune defenses against bacterial sepsis. J Infect Dis 187(Suppl 2):S385-S390
6. Thiele M, Bernhagen J (2005) Link between macrophage migration inhibitory factor and cellular redox regulation. Antioxid Redox Signal 7:1234-1248
7. Kudrin A, Ray D (2008) Cunning factor: macrophage migration inhibitory factor as a redox-regulated target. Immunol Cell Biol 86:232-238
8. Burke-Gaffney A, Callister ME, Nakamura H (2005) Thioredoxin: friend or foe in human disease? Trends Pharmacol Sci 26:398-404
9. Callister ME, Burke-Gaffney A, Quinlan GJ, Betts H, Nadel S, Evans TW (2007) Persistently low plasma thioredoxin is associated with meningococcal septic shock in children. Intensive Care Med 33:364-367
10. Hofer S, Rosenhagen C, Nakamura H, Yodoi J, Bopp C, Zimmermann JB, Goebel M, Schemmer P, Hoffmann K, Schulze-Osthoff K, Breitkreutz R, Weigand MA (2009) Thioredoxin in human and experimental sepsis. Crit Care Med 37:2155-2159
11. Tamaki H, Nakamura H, Nishio A, Nakase H, Ueno S, Uza N, Kido M, Inoue S, Mikami S, Asada M, Kiriya K, Kitamura H, Ohashi S, Fukui T, Kawasaki K, Matsuura M, Ishii Y, Okazaki K, Yodoi J, Chiba T (2006) Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production. Gastroenterology 131:1110-1121
12. Endo S, Aikawa N, Fujishima S, Sekine I, Kogawa K, Yamamoto Y, Kushimoto S, Yukioka H, Kato N, Totsuka K, Kikuchi K, Ikeda T, Ikeda K, Yamada H, Harada K, Satomura S (2008) Usefulness of procalcitonin serum level for the discrimination of severe sepsis from sepsis: a multicenter prospective study. J Infect Chemother 14:244-249
13. Bone RC, Sibbald WJ, Sprung CL (1992) The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 101:1481-1483
14. Callister ME, Burke-Gaffney A, Quinlan GJ, Nicholson AG, Florio R, Nakamura H, Yodoi J, Evans TW (2006) Extracellular thioredoxin levels are increased in patients with acute lung injury. Thorax 61:521-527
15. Nakamura H, De Rosa S, Roederer M, Anderson MT, Dubs JG, Yodoi J, Holmgren A, Herzenberg LA (1996) Elevation of plasma thioredoxin levels in HIV-infected individuals. Int Immunol 8:603-611
16. Lehmann LE, Novender U, Schroeder S, Pietsch T, von Spiegel T, Putensen C, Hoeft A, Stuber F (2001) Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med 27:1412-1415
17. Bozza FA, Gomes RN, Japiassu AM, Soares M, Castro-Faria-Neto HC, Bozza PT, Bozza MT (2004) Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 22:309-313
18. Gando S, Nishihira J, Kobayashi S, Morimoto Y, Nanzaki S, Kemmotsu O (2001) Macrophage migration inhibitory factor is a critical mediator of systemic inflammatory response syndrome. Intensive Care Med 27:1187-1193
19. Emonts M, Sweep FC, Grebenchtchikov N, Geurts-Moespot A, Knaup M, Chanson AL, Erard V, Renner P, Hermans PW, Hazelzet JA, Calandra T (2007) Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin Infect Dis 44:1321-1328
20. Livaditi O, Kotanidou A, Psarra A, Dimopoulou I, Sotiropoulou C, Augustatou K, Papasteriades C, Armaganidis A, Roussos C, Orfanos SE, Douzinas EE (2006) Neutrophil CD64 expression and serum IL-8: sensitive early markers of severity and outcome in sepsis. Cytokine 36:283-290
21. Buyukberber N, Buyukberber S, Sevinc A, Camci C (2009) Cytokine concentrations are not predictive of bacteremia in febrile neutropenic patients. Med Oncol 26:55-61
22. Netea MG, Kullberg BJ, Blok WL, Netea RT, van der Meer JW (1997) The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood 89:577-582
23. Ohashi S, Nishio A, Nakamura H, Kido M, Kiriya K, Asada M, Tamaki H, Fukui T, Kawasaki K, Watanabe N, Yodoi J, Okazaki K, Chiba T (2006) Clinical significance of serum thioredoxin 1 levels in patients with acute pancreatitis. Pancreas 32:264-270
24. Willeke P, Gaubitz M, Schotte H, Maaser C, Domschke W, Schluter B, Becker H (2007) Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjogren's syndrome. Arthritis Res Ther 9:R43
25. Kondo N, Ishii Y, Son A, Sakakura-Nishiyama J, Kwon YW, Tanito M, Nishinaka Y, Matsuo Y, Nakayama T, Taniguchi M, Yodoi J (2004) Cysteinedependent immune regulation by TRX and MIF/GIF family proteins. Immunol Lett 92:143-147
26. Sato A, Hara T, Nakamura H, Kato N, Hoshino Y, Kondo N, Mishima M, Yodoi J (2006) Thioredoxin-1 suppresses systemic inflammatory responses against cigarette smoking. Antioxid Redox Signal 8:1891-1896
27. Bach JP, Deuster O, Balzer-Geldsetzer M, Meyer B, Dodel R, Bacher M (2009) The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer 115:2031-2040
28. Marks PA (2006) Thioredoxin in cancer-role of histone deacetylase inhibitors. Semin Cancer Biol 16:436-443
29. Neilly IJ, Copland M, Haj M, Adey G, Benjamin N, Bennett B (1995) Plasma nitrate concentrations in neutropenic and non-neutropenic patients with suspected septicaemia. Br J Haematol 89:199-202